Suppr超能文献

多发性骨髓瘤与肾衰竭:一家中心的经验

Multiple myeloma and renal failure: one center's experience.

作者信息

Magee C, Vella J P, Tormey W P, Walshe J J

机构信息

Department of Nephrology, Beaumont Hospital, Dublin, Ireland.

出版信息

Ren Fail. 1998 Jul;20(4):597-606. doi: 10.3109/08860229809045152.

Abstract

Renal involvement remains a major complication of multiple myeloma, particularly in advanced disease. A retrospective analysis was performed of the modes of presentation, treatment and outcome of all patients with multiple myeloma treated in our renal unit between 1987 and 1996. Thirty-four patients were identified: in 26 (76%) the diagnosis of myeloma was made only after referral. Light chains were the most common paraprotein in both serum and urine. Twenty-one (62%) patients underwent renal biopsy: myeloma cast nephropathy was the predominant histological finding in 16 cases. Thirty-one (91%) patients had severe renal failure (GFR < 20 mL/min), with 28 (82%) requiring dialysis within 2 weeks of admission. Despite treatment of presumed precipitaing causes of acute deterioration in renal function, only 1 of these 28 patients subsequently became independent of dialysis. Most had advanced stage myeloma: 29 (85%) were Durie-Salmon stage II or III. Hypercalcemia, sepsis and pathological fractures were the principal complications. Median survival overall was 5 months. The main causes of death were withdrawal of renal replacement therapy (overwhelming myeloma, severe debilitation) and sepsis. Nineteen (56%) patients received long-term (> 1 month) renal replacement therapy with a median survival of 8 months. However, five of these (26%) have survived for more than 12 months on dialysis and report a good quality of life.

摘要

肾脏受累仍然是多发性骨髓瘤的主要并发症,尤其是在疾病晚期。对1987年至1996年间在我们肾脏科接受治疗的所有多发性骨髓瘤患者的临床表现、治疗方法和预后进行了回顾性分析。共确定了34例患者:其中26例(76%)在转诊后才确诊为骨髓瘤。轻链是血清和尿液中最常见的副蛋白。21例(62%)患者接受了肾活检:16例主要组织学表现为骨髓瘤管型肾病。31例(91%)患者出现严重肾衰竭(肾小球滤过率<20 mL/分钟),其中28例(82%)在入院后2周内需要透析。尽管对肾功能急性恶化的推测性诱发原因进行了治疗,但这28例患者中只有1例随后不再依赖透析。大多数患者处于骨髓瘤晚期:29例(85%)为Durie-Salmon分期II期或III期。高钙血症、败血症和病理性骨折是主要并发症。总体中位生存期为5个月。主要死亡原因是停止肾脏替代治疗(严重骨髓瘤、极度虚弱)和败血症。19例(56%)患者接受了长期(>1个月)肾脏替代治疗,中位生存期为8个月。然而,其中5例(26%)在透析后存活超过12个月,且生活质量良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验